Differential effects of fondaparinux and bemiparin on angiogenic and vasculogenesis-like processes

Thrombosis Research

Volumn 130, Issue 3, 2012, Pages

  Da Pozzo, Eleonora ^a   Barsotti, Maria Chiara ^a   Bendinelli, Sara ^a   Martelli, Alma ^a   Calderone, Vincenzo ^a   Balbarini, Alberto ^a   Martini, Claudia ^a   Di Stefano, Rossella ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Angiogenesis; Endothelial progenitor cells; Glyco anticoagulants; Human umbilical vein endothelial cells; PI3 kinase AKT; Vasculogenesis

Indexed keywords

BEMIPARIN; FONDAPARINUX; HEPARIN CALCIUM; MATRIGEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXPERIMENTAL MODEL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTICOAGULANTS; CELL DIFFERENTIATION; CELLS, CULTURED; ENDOTHELIAL CELLS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; POLYSACCHARIDES; STEM CELLS;

EID: 84865244127     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.03.013     Document Type: Article

References (72)

1. K.P. Singh, M.T. Roe, E.D. Peterson, A.Y. Chen, K.W. Mahaffey, and S.G. Goodman Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative J Thromb Thrombolysis 21 2006 211 220
2. T. Ibbotson, and K.L. Goa Enoxaparin: an update of its clinical use in the management of acute coronary syndromes Drugs 62 2002 1407 1430
3. M.B. Kadakia, N.R. Desai, K.P. Alexander, A.Y. Chen, J.M. Foody, and C.P. Cannon Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction A Report From the NCDR ACTION Registry-GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines) JACC Cardiovasc Interv 3 2010 1166 1177
4. T.Z. Potsis, C. Katsouras, and J.A. Goudevenos Avoiding and managing bleeding complications in patients with non-ST-segment elevation acute coronary syndromes Angiology 60 2009 148 158
5. J.C. Nicolau, M. Cohen, and G. Montalescot Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes J Cardiovasc Pharmacol 53 2009 440 445
6. J. Martinez-Gonzalez, L. Vila, and C. Rodriguez Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism Expert Rev Cardiovasc Ther 6 2008 793 802
7. J. Martínez-González, and C. Rodríguez New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin Expert Rev Cardiovasc Ther 8 2010 625 634
8. A.C. Spyropoulos Brave new world: the current and future use of novel anticoagulants Thromb Res 123 Suppl. 1 2008 S29 S35
9. R. Di Stefano, F. Felice, and A. Balbarini Angiogenesis as risk factor for plaque vulnerability Curr Pharm Des 15 2009 1095 1106
10. R.K. Jain, A.V. Finn, F.D. Kolodgie, H.K. Gold, and R. Virmani Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization Nat Clin Pract Cardiovasc Med 4 2007 491 502
11. T. Asahara, T. Murohara, A. Sullivan, M. Silver, R. van der Zee, and T. Li Isolation of putative progenitor endothelial cells for angiogenesis Science 275 1997 964 967
12. Q. Xu The impact of progenitor cells in atherosclerosis Nat Clin Pract Cardiovasc Med 3 2006 94 101
13. C. Kalka, H. Masuda, T. Takahashi, W.M. Kalka-Moll, M. Silver, and M. Kearney Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization Proc Natl Acad Sci U S A 97 2000 3422 3427
14. T. Umemura, and Y. Higashi Endothelial progenitor cells: therapeutic target for cardiovascular diseases J Pharmacol Sci 108 2008 1 6
15. J. Hur, C.H. Yoon, H.S. Kim, J.H. Choi, H.J. Kang, and K.K. Hwang Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis Arterioscler Thromb Vasc Biol 24 2004 288 293
16. R. Gulati, D. Jevremovic, T.E. Peterson, S. Chatterjee, V. Shah, and R.G. Vile Diverse origin and function of cells with endothelial phenotype obtained from adult human blood Circ Res 93 2003 1023 1025
17. J. Rehman, J. Li, C.M. Orschell, and K.L. March Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors Circulation 107 2003 1164 1169
18. C. Urbich, A. Aicher, C. Heeschen, E. Dernbach, W.K. Hofmann, and A.M. Zeiher Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells J Mol Cell Cardiol 39 2005 733 742
19. M.C. Yoder, L.E. Mead, D. Prater, T.R. Krier, K.N. Mroueh, and F. Li Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals Blood 109 2007 1801 1809
20. K. Norrby Low-molecular-weight heparins and angiogenesis Apmis 114 2006 79 102
21. H.P. Gerber, A. McMurtrey, J. Kowalski, M. Yan, B.A. Keyt, and V. Dixit Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation J Biol Chem 273 1998 30336 30343
22. G.D. Thakker, D.P. Hajjar, W.A. Muller, and T.K. Rosengart The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling J Biol Chem 274 1999 10002 10007
23. R. Di Stefano, M.C. Barsotti, E. Melillo, M. Iorio, T. Santoni, and C. Armani The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia Thromb Haemost 100 2008 871 877
24. M.C. Barsotti, A. Magera, C. Armani, F. Chiellini, F. Felice, and D. Dinucci Fibrin acts as biomimetic niche inducing both differentiation and stem cell marker expression of early human endothelial progenitor cells Cell Prolif 44 2011 33 48
25. R. Di Stefano, M.C. Barsotti, C. Armani, T. Santoni, R. Lorenzet, and A. Balbarini Human peripheral blood endothelial progenitor cells synthesize and express functionally active tissue factor Thromb Res 123 2009 925 930
26. D.N. Prater, J. Case, D.A. Ingram, and M.C. Yoder Working hypothesis to redefine endothelial progenitor cells Leukemia 21 2007 1141 1149
27. D.A. Ingram, N.M. Caplice, and M.C. Yoder Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells Blood 106 2005 1525 1531
28. I. Arnaoutova, J. George, H.K. Kleinman, and G. Benton The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art Angiogenesis 12 2009 267 274
29. R.J. Hettiarachchi, S.M. Smorenburg, J. Ginsberg, M. Levine, M.H. Prins, and H.R. Buller Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread Thromb Haemost 82 1999 947 952
30. P. Prandoni, A. Falanga, and A. Piccioli Cancer and venous thromboembolism Lancet Oncol 6 2005 401 410
31. R.G. Bagley, J. Walter-Yohrling, X. Cao, W. Weber, B. Simons, and B.P. Cook Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells Cancer Res 63 2003 5866 5873
32. S. Purhonen, J. Palm, D. Rossi, N. Kaskenpää, I. Rajantie, and S. Ylä-Herttuala Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth Proc Natl Acad Sci U S A 105 2008 6620 6625
33. B. Doyle, and N. Caplice Plaque neovascularization and antiangiogenic therapy for atherosclerosis J Am Coll Cardiol 49 2007 2073 2080
34. M. Sata Role of circulating vascular progenitors in angiogenesis, vascular healing, and pulmonary hypertension: lessons from animal models Arterioscler Thromb Vasc Biol 26 2006 1008 1014
35. J. George, A. Afek, A. Abashidze, H. Shmilovich, V. Deutsch, and J. Kopolovich Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice Arterioscler Thromb Vasc Biol 25 2005 2636 2641
36. J. Hirsh, T.E. Warkentin, S.G. Shaughnessy, S.S. Anand, J.L. Halperin, and R. Raschke Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety Chest 119 2001 64S 94S
37. A. Bikfalvi, S. Klein, G. Pintucci, and D.B. Rifkin Biological roles of fibroblast growth factor-2 Endocr Rev 18 1997 26 45
38. T. Spivak-Kroizman, M.A. Lemmon, I. Dikic, J.E. Ladbury, D. Pinchasi, and J. Huang Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation Cell 79 1994 1015 1024
39. A.D. DiGabriele, I. Lax, D.I. Chen, C.M. Svahn, M. Jaye, and J. Schlessinger Structure of a heparin-linked biologically active dimer of fibroblast growth factor Nature 393 1998 812 817
40. J. Rak, and J.I. Weitz Heparin and angiogenesis: size matters! Arterioscler Thromb Vasc Biol 23 2003 1954 1955
41. A.A. Khorana, A. Sahni, O.D. Altland, and C.W. Francis Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight Arterioscler Thromb Vasc Biol 23 2003 2110 2115
42. A. Collen, S.M. Smorenburg, E. Peters, F. Lupu, P. Koolwijk, and C. Van Noorden Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro Cancer Res 60 2000 6196 6200
43. A. Navarro-Quilis, E. Castellet, E. Rocha, J. Paz-Jimenez, and A. Planes Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial J Thromb Haemost 1 2003 425 432
44. V.V. Kakkar, M. Gebska, Z. Kadziola, N. Saba, and P. Carrasco Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis Thromb Haemost 89 2003 674 680
45. D. Marsland, S.C. Mears, and S.L. Kates Venous thromboembolic prophylaxis for hip fractures Osteoporos Int 21 2010 S593-S04
46. R.L. Bick, E.P. Frenkel, J. Walenga, J. Fareed, and D.A. Hoppensteadt Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use Hematol Oncol Clin North Am 19 2005 1 51
47. D. Hoppensteadt, J.M. Walenga, J. Fareed, and R.L. Bick Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation Hematol Oncol Clin North Am 17 2003 313 341
48. S.A. Mousa, and S. Mohamed Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor Thromb Haemost 92 2004 627 633
49. S.A. Mousa, and S. Mohamed Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy Oncol Rep 12 2004 683 688
50. A. Bierhaus, and P.P. Nawroth Antiangiogenic properties of low molecular weight heparin - does tissue factor provide the answer? Thromb Haemost 92 2004 438 439
51. S.A. Mousa Anti-thrombotics in thrombosis and cancer Future Oncol 1 2005 395 403
52. J. Hasan, S.D. Shnyder, A.R. Clamp, A.T. McGown, R. Bicknell, and M. Presta Heparin octasaccharides inhibit angiogenesis in vivo Clin Cancer Res 11 2005 8172 8179
53. D. Chabut, A.M. Fischer, S. Colliec-Jouault, I. Laurendeau, S. Matou, and B. Le Bonniec Low molecular weight fucoidan and heparin enhance the basic fibroblast growth factor-induced tube formation of endothelial cells through heparan sulfate-dependent alpha6 overexpression Mol Pharmacol 64 2003 696 702
54. X. Xu, and Y. Dai Heparin: an intervenor in cell communication J Cell Mol Med 14 2010 175 180
55. N.S. Gandhi, and R.L. Mancera Free energy calculations of glycosaminoglycan-protein interactions Glycobiology 19 2009 1103 1115
56. R.D. Frank, T. Holscher, G. Schabbauer, M. Tencati, R. Pawlinski, and J.I. Weitz A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury Thromb Haemost 96 2006 802 806
57. R.D. Frank, G. Schabbauer, T. Holscher, Y. Sato, M. Tencati, and R. Pawlinski The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia-reperfusion injury J Thromb Haemost 3 2005 531 540
58. J.Y. Wang, Y.T. Lee, P.F. Chang, and L.Y. Chau Hemin promotes proliferation and differentiation of endothelial progenitor cells via activation of AKT and ERK J Cell Physiol 219 2009 617 625
59. S.E. Guimond, and J.E. Turnbull Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides Curr Biol 9 1999 1343 1346
60. L. Lundin, H. Larsson, J. Kreuger, S. Kanda, U. Lindahl, and M. Salmivirta Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis J Biol Chem 275 2000 24653 24660
61. R. Castelli, F. Porro, and P. Tarsia The heparins and cancer: review of clinical trials and biological properties Vasc Med 9 2004 205 213
62. S.M. Smorenburg, and C.J. Van Noorden The complex effects of heparins on cancer progression and metastasis in experimental studies Pharmacol Rev 53 2001 93 105
63. J.L. Giraux, S. Matou, A. Bros, J. Tapon-Bretaudière, D. Letourneur, and A.M. Fischer Modulation of human endothelial cell proliferation and migration by fucoidan and heparin Eur J Cell Biol 77 1998 352 359
64. S. Goetze, F. Eilers, A. Bungenstock, U. Kintscher, P. Stawowy, and F. Blaschke PPAR activators inhibit endothelial cell migration by targeting Akt Biochem Biophys Res Commun 293 2002 1431 1437
65. S. Namkoong, S.J. Lee, C.K. Kim, Y.M. Kim, H.T. Chung, and H. Lee Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells Exp Mol Med 37 2005 588 600
66. Y. Rikitake, K. Hirata, S. Kawashima, iM Ozak, T. Takahashi, and W. Ogawa Involvement of endothelial nitric oxide in sphingosine-1-phosphate-induced angiogenesis Arterioscler Thromb Vasc Biol 22 2002 108 114
67. A. Uruno, A. Sugawara, H. Kanatsuka, S. Arima, Y. Taniyama, and M. Kudo Hepatocyte growth factor stimulates nitric oxide production through endothelial nitric oxide synthase activation by the phosphoinositide 3-kinase/Akt pathway and possibly by mitogen-activated protein kinase kinase in vascular endothelial cells Hypertens Res 27 2004 887 895
68. D. Hanjaya-Putra, J. Yee, D. Ceci, R. Truitt, D. Yee, and S. Gerecht Vascular endothelial growth factor and substrate mechanics regulate in vitro tubulogenesis of endothelial progenitor cells J Cell Mol Med 14 2010 2436 2447
69. S.A. Mousa, and L.J. Petersen Anti-cancer properties of low-molecular-weight heparin: preclinical evidence Thromb Haemost 102 2009 258 267
70. I. Debergh, N. Van Damme, P. Pattyn, M. Peeters, and W.P. Ceelen The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model Br J Cancer 102 5 2010 837 843
71. D.Y. Lee, S.W. Lee, S.K. Kim, M. Lee, H.W. Chang, and H.T. Moon Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells Pharm Res 26 2009 2667 2676
72. J.W. Park, O.C. Jeon, S.K. Kim, T.A. Al-Hilal, S.J. Jin, and H.T. Moon High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives J Control Release 148 2010 317 326